At the New Mexico Cancer Center in Albuquerque, groundbreaking treatments and compassionate care are changing lives for men facing prostate cancer. With a team of dedicated specialists, their ...

A systematic review highlights the potential of genomic tests in prostate cancer treatment decisions but calls for more data ...

Incorporating biomarkers into standard practice enhances diagnostic accuracy, supporting confident treatment decisions and optimizing care.

For patients with localized prostate cancer (PCa), tissue-based genomic classifiers (GCs) do not consistently influence risk ...

The drug, known as NXP800, works by targeting the heat shock factor 1 (HSF1) pathway, a cellular protective mechanism that is ...

Tissue-based genomic classifier tests, developed to improve prostate cancer risk assessment and treatment recommendations, ...

Genomic classifier (GC) tests do not appear to consistently influence risk classification or treatment decisions for patients ...

Annual check-ups save lives by detecting prostate issues early, yet many men avoid these crucial tests due to fear or misconceptions. Prostate health ...

Prostate cancer usually develops slowly, so there may be no signs of the health condition for many years, but once the tumour ...